Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568630 · ClinicalTrials.gov registry record
Blood Markers of Early Pancreas Cancer
A clinical trial of Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by University of Nebraska.
- Recruiting
- Registry status
- 1,250
- Enrollment target
- 1
- Study location
NCT03568630 is a study of Diabetes Mellitus, Type 2 and PreDiabetes that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 1,250 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03568630, a study of Diabetes Mellitus, Type 2 and PreDiabetes, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- 1,250 participants
- Enrollment target
- 1
- Study location
Study Summary
Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.
Conditions Studied
Study Locations (1)
Nebraska
- Unversity of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568630
The ClinicalTrials.gov registry entry for NCT03568630 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 0 interventions.
NCT03568630 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT03568630 about?
NCT03568630 is a clinical study titled "Blood Markers of Early Pancreas Cancer". Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose...
What is the current status of trial NCT03568630?
This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2018-07-26. Estimated completion is 2028-07.
What conditions does trial NCT03568630 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, PreDiabetes, Chronic Pancreatitis, Genetic Predisposition to Disease, Pancreas Cyst.
Who is sponsoring clinical trial NCT03568630?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03568630 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.